CD7 CAR-T therapy for T-cell cancers that returned
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be a type of T-cell cancer that has the CD7 marker on the cancer cells.
- You must have already tried all standard treatments (like chemo or a stem cell transplant) and they didn't work or you couldn't tolerate them.
- You are between 1 and 70 years old.
- You are generally able to care for yourself (ECOG score 0–2) and your doctor thinks you have at least 2 months to live.
- You do not have severe heart, lung, kidney, or liver failure, uncontrolled infections, other cancers, or serious mental health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests a new type of immune cell therapy (multi-CAR T cells) designed to target and kill cancer cells that have a marker called CD7. It may help people with certain blood cancers that have not responded well to other treatments.
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
This trial tests a new type of cell therapy (4SCAR7U) designed to target and kill cancer cells that carry a protein called CD7. It is for people with blood cancers that have not responded to other treatments.
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
This trial tests a new type of immunotherapy called CAR-T that targets a protein called CD7 on cancer cells. It is for people with peripheral T-cell lymphoma that has come back or not responded to at least one prior treatment.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.